Inventor · disambiguated record
Sharlene Adams
Also filed as: ADAMS SHARLENE
13 granted patents·9 pending applications·253 citations·filing 1997–2023
92Inventor score
Files withMERRIMACK PHARMACEUTICALS INC7POINT THERAPEUTICS INC6ANTIGEN EXPRESS INC3IMMUNOGEN INC3UNIV MASSACHUSETTS2
Top patents by PatentIndex Score
22 records- 0193US6300314B1Hematopoietic stimulationPOINT THERAPEUTICS INC·Filed 1999·Granted Oct 9, 2001·106 cites·36 claims
- 0291US8476409B2Bispecific anti-IGF-1R and anti-ErbB3 antibodiesBAUM JASON·Filed 2012·Granted Jul 2, 2013·22 cites·15 claims
- 0390US6770628B2Hematopoietic stimulationPOINT THERAPEUTICS INC·Filed 2001·Granted Aug 3, 2004·34 cites·21 claims
- 0483US7067489B2Hematopoietic stimulationPOINT THERAPEUTICS INC·Filed 2004·Granted Jun 27, 2006·14 cites·16 claims
- 0583US5919639AIi peptide therapeutics to enhance antigen presentationUNIV MASSACHUSETTS·Filed 1997·Granted Jul 6, 1999·40 cites·8 claims
- 0682US7541334B2Hybrid peptides modulate the immune responseANTIGEN EXPRESS INC·Filed 2007·Granted Jun 2, 2009·3 cites·1 claims
- 0779US9556274B2Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 31, 2017·2 cites·10 claims
- 0877US7205274B2Hybrid peptides modulate the immune responseANTIGEN EXPRESS INC·Filed 2002·Granted Apr 17, 2007·6 cites·3 claims
- 0974US11701428B2Therapeutic combinations comprising anti-CD123 immunoconjugatesIMMUNOGEN INC·Filed 2020·Granted Jul 18, 2023·1 cites·40 claims
- 1073US9527914B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Dec 27, 2016·1 cites·6 claims
- 1171US6432409B1Hybrid peptides modulate the immune responseANTIGEN EXPRESS INC·Filed 1999·Granted Aug 13, 2002·24 cites·6 claims
- 1263US2024033371A1Therapeutic combinations comprising anti-cd123 immunoconjugatesIMMUNOGEN INC·Filed 2023·Application pending·0 cites
- 1361US9938346B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Apr 10, 2018·0 cites·24 claims
- 1458US2007135354A1Hematopoietic stimulationPOINT THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 1552US2015231219A1Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1650US2018036395A1Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1749US2005084490A1Boroproline compound combination therapyPOINT THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 1849US2004077601A1Methods and compositions relating to isoleucine boroproline compoundsPOINT THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 1940US2019160089A1Combination treatment with antibody-drug conjugates and cytarabineIMMUNOGEN INC·Filed 2018·Application pending·0 cites
- 2039US2018169230A1Combination cancer therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2137US2017096492A1DOSAGE AND ADMINISTRATION OF ANTI-IGF-1R, ANTI-ErbB3 BISPECIFIC ANTIBODIES, USES THEREOF AND METHODS OF TREATMENT THEREWITHMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2233US6835382B2Ii peptide therapeutics to enhance antigen presentationUNIV MASSACHUSETTS·Filed 1999·Granted Dec 28, 2004·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when Sharlene Adams files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →